Thornberry Nancy sold $262K of DNLI
Thornberry Nancy sold 11,439 shares of Denali Therapeutics Inc. (DNLI) at an average of $22.90 ($22.85–$23.74, $0.26M total) across 2 trades on 2026-09-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing provides the first public disclosure of a director’s recent equity sale, offering a data point for short‑term sentiment.
Market read
Primary source Form 4 filing; modest insider sell may cause slight price pressure but unlikely to move the broader market.
What to watch
Holding after sale remains 19,686 shares, preserving a sizable insider stake.
Background
Denali Therapeutics (NASDAQ: DNLI) is a clinical‑stage biotech focused on neurodegenerative diseases.
Ticker impact
Director Thornberry Nancy sold 11,439 shares for $261,928 via a 10b5‑1 plan on Sep 2, 2026.
Potential slight dip or flat‑line as the market digests the $262K sale.
A director’s 10b5‑1 sale signals personal liquidity need; size is small relative to market cap, so impact is limited.
Market effects
Minimal; biotech sector not broadly affected by a single director’s modest sale.
None
None
Counterpoint
The sale may be routine under a pre‑arranged plan and not indicative of insider concern.
Key entities
- CompanyDenali Therapeutics Inc.
Biotech firm whose stock is subject to the insider sale.
- IndividualThornberry Nancy
Director of Denali Therapeutics executing a 10b5‑1 sale.
